These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 15493002)
41. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eigtved A; Andersson AP; Dahlstrøm K; Rabøl A; Jensen M; Holm S; Sørensen SS; Drzewiecki KT; Højgaard L; Friberg L Eur J Nucl Med; 2000 Jan; 27(1):70-5. PubMed ID: 10654150 [TBL] [Abstract][Full Text] [Related]
42. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533 [TBL] [Abstract][Full Text] [Related]
43. Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging. Basu S; Alavi A Clin Nucl Med; 2007 May; 32(5):388-9. PubMed ID: 17452870 [No Abstract] [Full Text] [Related]
44. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151 [TBL] [Abstract][Full Text] [Related]
45. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging. Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460 [TBL] [Abstract][Full Text] [Related]
46. PET/Computed Tomography and Patient Outcomes in Melanoma. Rohren EM PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089 [TBL] [Abstract][Full Text] [Related]
48. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Krug B; Dietlein M; Groth W; Stützer H; Psaras T; Gossmann A; Scheidhauer K; Schicha H; Lackner K Acta Radiol; 2000 Sep; 41(5):446-52. PubMed ID: 11016764 [TBL] [Abstract][Full Text] [Related]
49. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Mijnhout GS; Comans EF; Raijmakers P; Hoekstra OS; Teule GJ; Boers M; De Gast GC; Adèr HJ Nucl Med Commun; 2002 May; 23(5):475-81. PubMed ID: 11973489 [TBL] [Abstract][Full Text] [Related]
50. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925 [TBL] [Abstract][Full Text] [Related]
51. F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Vasanawala MS; Wang Y; Quon A; Gambhir SS Clin Nucl Med; 2006 Sep; 31(9):534-7. PubMed ID: 16921276 [TBL] [Abstract][Full Text] [Related]
52. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies. Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571 [TBL] [Abstract][Full Text] [Related]
53. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
54. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295 [TBL] [Abstract][Full Text] [Related]
55. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846 [TBL] [Abstract][Full Text] [Related]
56. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study. Klein M; Freedman N; Lotem M; Marciano R; Moshe S; Gimon Z; Chisin R Nuklearmedizin; 2000; 39(3):56-61. PubMed ID: 10834191 [TBL] [Abstract][Full Text] [Related]
57. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Menda Y; Graham MM Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243 [TBL] [Abstract][Full Text] [Related]
58. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374 [TBL] [Abstract][Full Text] [Related]
59. Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases. Bastiaannet E; Hoekstra OS; Oyen WJ; Jager PL; Wobbes T; Hoekstra HJ Ann Surg Oncol; 2006 Jul; 13(7):919-26. PubMed ID: 16788752 [TBL] [Abstract][Full Text] [Related]
60. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]